Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6511 to 6525 of 7707 results

  1. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis [ID388]

    Discontinued [GID-TAG372]

  2. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued [GID-TA10711]

  3. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued [GID-NG10059]

  4. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued [GID-TAG420]

  5. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued [GID-TAG526]

  6. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued [GID-TA10157]

  7. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued [GID-TA10363]

  8. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued [GID-TAG424]

  9. Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

    Discontinued [GID-TA10070]

  10. Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

    Discontinued [GID-TA10923]

  11. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued [GID-TAG421]

  12. PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

    This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.

  13. UroShield for preventing catheter-associated urinary tract infections (MIB191)

    This advice has been updated and replaced by NICE medical technologies guidance 69.

  14. Alpha-Stim AID for anxiety (MIB193)

    This advice has been updated and replaced by NICE medical technologies guidance 56.

  15. DyeVert for reducing contrast media in coronary and peripheral angiography (MIB196)

    This advice has been updated and replaced by NICE medical technologies guidance 60.